Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
To position istaroxime for Phase 3 readiness, WINT launched the small Phase 2 study in SCAI Stage C. SCAI Stage C cardiogenic shock is a more severely ill patient population than the participants ...
Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial Receive the the latest news, research, and presentations from major ...
Zacks Small Cap Research on MSN16d
WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating CoverageWINT READ THE FULL WINT RESEARCH REPORT Multiple Programs Focus on Unmet Needs In Cardiogenic Shock & AHF Pennsylvania-based Windtree Therapeutics, Inc. (NASDAQ:WINT) is a biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback